MTOR kinase mutations and methods of use thereof
AssigneeRutgers, The State University of New Jersey
InventorSteven Zheng
Life of this patent
Estimating the term…
Abstract
Certain embodiments of the invention provide a method of detecting the presence of a biomarker associated with resistance to an mTOR kinase inhibitor in a subject, comprising determining the presence of the biomarker in a physiological sample from the subject, wherein the sample comprises a nucleic acid.
Claims11
A method of treating cancer in a subject comprising:
- a) detecting the presence or absence of a biomarker in a physiological sample obtained from the subject, wherein the sample comprises a cancer cell(s), and wherein the biomarker comprises 1) at least one mutation in a mTOR polynucleotide that results in an amino acid substitution at residue L2185 of the mTOR polypeptide;
- or 2) a mutation at residue L2185 of a mTOR polypeptide;
- b) selecting an mTOR kinase inhibitor having a three-ring fused heterocyclic structure for administration to the subject if the presence of the biomarker is detected;
- and selecting an mTOR kinase inhibitor without a three-ring fused heterocyclic structure for administration to the subject if the absence of the biomarker is detected;
- and
- c) administering the selected mTOR kinase inhibitor to the subject to treat the cancer.
A method of treating cancer in a subject comprising administering a mTOR kinase inhibitor having a three-ring fused heterocyclic structure to the subject, wherein the cancer was determined to comprise 1) at least one mutation in a mTOR polynucleotide that results in an amino acid substitution at residue L2185 of a mTOR polypeptide;
- or 2) a mutation at residue L2185 of a mTOR polypeptide.
Dependencies are inferred from the claim text.